Stock Track | Verona Pharma Plunges Despite Positive Ohtuvayre Launch

Stock Track11-04

Shares of Verona Pharma plc (NASDAQ: VRNA), a biopharmaceutical company focused on respiratory diseases, plummeted by 5.66% on November 4, 2024, despite reporting strong initial sales of its newly launched product Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD).

In its third-quarter 2024 financial results, Verona Pharma announced net sales of $5.6 million for Ohtuvayre, which was approved by the FDA in June and commercially launched in August. The company reported positive adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients, highlighting the product's potential to redefine the treatment paradigm.

However, the company's net loss widened to $43.0 million in Q3 2024, compared to a net loss of $14.7 million in the same period last year. This significant increase in net loss was primarily driven by higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre and the buildup of the sales force.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153893092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153893092","market":"hk","top_or_hot":-1,"title":"Stock Track | Verona Pharma Plunges Despite Positive Ohtuvayre Launch","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ: VRNA), a biopharmaceutical company focused on respiratory diseases, plummeted by 5.66% on November 4, 2024, despite reporting strong initial sales of its newly launched product Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD).</p>\n\n<p>In its third-quarter 2024 financial results, Verona Pharma announced net sales of $5.6 million for Ohtuvayre, which was approved by the FDA in June and commercially launched in August. The company reported positive adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients, highlighting the product's potential to redefine the treatment paradigm.</p>\n\n<p>However, the company's net loss widened to $43.0 million in Q3 2024, compared to a net loss of $14.7 million in the same period last year. This significant increase in net loss was primarily driven by higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre and the buildup of the sales force.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Plunges Despite Positive Ohtuvayre Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Plunges Despite Positive Ohtuvayre Launch\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 22:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Verona Pharma plc (NASDAQ: VRNA), a biopharmaceutical company focused on respiratory diseases, plummeted by 5.66% on November 4, 2024, despite reporting strong initial sales of its newly ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1153893092","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153893092","pubTimestamp":1730730770,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc , a biopharmaceutical company focused on respiratory diseases, plummeted by 5.66% on November 4, 2024, despite reporting strong initial sales of its newly launched product Ohtuvayre  for the treatment of chronic obstructive pulmonary disease .In its third-quarter 2024 financial results, Verona Pharma announced net sales of $5.6 million for Ohtuvayre, which was approved by the FDA in June and commercially launched in August. The company reported positive adoption from ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"尽管Ohtuvayre推出积极，但维罗纳制药(Verona Pharma)股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ: VRNA), a biopharmaceutical company focused on respiratory diseases, plummeted by 5.66% on November 4, 2024, despite reporting strong initial sales of its newly launched product Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD).\nIn its third-quarter 2024 financial results, Verona Pharma announced net sales of $5.6 million for Ohtuvayre, which was approved by the FDA in June and commercially launched in August. The company reported positive adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients, highlighting the product's potential to redefine the treatment paradigm.\nHowever, the company's net loss widened to $43.0 million in Q3 2024, compared to a net loss of $14.7 million in the same period last year. This significant increase in net loss was primarily driven by higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre and the buildup of the sales force.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153893092"}